Blockchain Registration Transaction Record

Candel Therapeutics Reports Positive Phase 2 Trial Data for CAN-2409 in Pancreatic Cancer

Candel Therapeutics, Inc. (NASDAQ: CADL) reports positive phase 2 trial data for CAN-2409 in borderline resectable pancreatic cancer, showing promising results in improving overall survival for patients.

The release of updated survival data from Candel Therapeutics' phase 2 clinical trial of CAN-2409 in pancreatic cancer is significant as it demonstrates promising results in improving overall survival for patients with borderline resectable pancreatic cancer. This could potentially lead to a new treatment option for a disease that accounts for approximately 3% of all cancers in the U.S., impacting thousands of patients each year.